We recently demonstrated that neoadjuvant ARSI treatment of high-risk PCa patients resulted in significant enrichment of NF-κB signaling and a gene signature associated with neuroendocrine-like disease state (36). The gene discussed is NFKB1; the disease is posterior cortical atrophy.